| Name | Title | Contact Details |
|---|
AxxiTrials is a Irvington, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Complete Testing Solutions is a Gilbert, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
ZAGENO is on a mission to accelerate scientific innovation by streamlining biotech purchasing processes with its award-winning, first-of-its-kind e-commerce platform. With over 25 million product SKUs available from more than 5,000 unique product brands, ZAGENO makes online shopping for any research material convenient, efficient and reliable. The ZAGENO experience includes its Scientific Score, a best-in-class product rating system that offers unbiased, peer-reviewed ratings to support accurate purchasing decisions. Available on desktop, tablet, and mobile devices, ZAGENO makes biotech purchases easier than ever and is an ideal sales channel for suppliers and partners. Founded in 2015, the company is headquartered in the United States and has additional offices in Germany, and Poland.
Neoleukin Therapeutics emerged from the University of Washington Institute for Protein Design in January of 2019. We are creating next generation immunotherapies using breakthrough de novo protein design technology. We use natural protein complexes as inspiration to develop custom designed proteins with superior pharmaceutical properties.
Spring Bank Pharmaceuticals (NASDAQ: SBPH) is a clinical-stage biopharmaceutical company engaged in the discovery and development of a novel class of therapeutics using our proprietary small molecule nucleic acid hybrid (SMNH) chemistry platform. SMNH compounds are small segments of nucleic acids that the company designs to selectively target and modulate the activity of specific proteins implicated in various disease states. Spring Bank is developing its most advanced SMNH product candidate, inarigivir soproxil (formerly referred to as SB 9200), for the treatment of viral diseases, including hepatitis B virus (HBV), and other SMNH product candidates, including SB 11285, the company`s lead immunotherapeutic agent for the treatment of selected cancers through the activation of the STimulator of Interferon Genes, or STING, pathway.